Apricus Biosciences Announces the Launch of Its Novel

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Portugal, Ireland and Poland by Recordati

SAN DIEGO, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the launch of Vitaros ® , Apricus’ novel on-demand topical cream for the treatment of erectile dysfunction (ED), in Portugal, Ireland and Poland by Recordati.

Richard Pascoe, Chief Executive Officer of Apricus, commented, “We are pleased to announce the launch of Vitaros in these important ED markets by our partner Recordati.  With these launches, Vitaros is now commercially available in seven European countries, including Spain, where Recordati successfully introduced the product as Virirec ™ a year ago.  Moreover, we expect additional approvals and product launches later this year and early next year by our commercialization partners in Europe, Latin America and the Middle East.  Looking forward, our key strategic goals continue to be achieving profitability through Vitaros revenue growth and obtaining Vitaros FDA approval in the United States in 2017.”

In February 2014, Apricus signed an exclusive license agreement with Recordati to market Vitaros in Spain, Russia, Turkey, Ireland and certain other European and African countries and received an upfront payment of $2.4 million.  Under the terms of the agreement, Apricus is eligible to receive up to approximately $39.7 million from Recordati in additional milestones, plus double-digit tiered royalties in the ten to twenty percent range based on Recordati’s net sales of the product in the territory.

Vitaros is a new entrant into these ED treatment markets, offering a product profile making it appealing to certain patients.  Vitaros is a topical ED cream that delivers rapid onset (generally five to thirty minutes) and treatment duration of approximately one to two hours.  Vitaros’ local delivery provides an alternative for patients, but particularly those with complications that preclude them from using the orally delivered systemic treatments or who prefer to avoid the injectable forms of alprostadil.

About Recordati

Established in 1926, Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange (Bloomberg REC IM), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Recordati is headquartered in Milan, Italy, with operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in the United States of America and in North Africa. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new drug entities within the urogenital therapeutic area and of treatments for rare diseases.

For further information, please visit the Recordati website: www.recordati.com .

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ commercial product, Vitaros ® , for the treatment of erectile dysfunction, is approved in Europe, part of the Middle East and Canada and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product candidate, RayVa ™ , its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon.

For further information on Apricus, visit http://www.apricusbio.com .

*Vitaros ® is a registered trademark of NexMed International Limited.  Such trademark is registered in certain countries throughout the world and pending registration in the United States.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: references to potential Vitaros approvals and product launches by Apricus’ commercial partners in additional countries and the timing thereof; the potential for the product to achieve commercial success generally or in any specific territory, including Portugal, Ireland and Poland, and for Apricus to receive future milestone and royalty revenue; the ability of Apricus to achieve profitability based on Vitaros revenue growth; and the timing of approval, if any, by the Food and Drug Administration (FDA) of Vitaros in the United States. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside of Apricus’ control, including, but not limited to: Apricus’ dependence on its commercial partners to carry out the commercial launch or grow sales of Vitaros in various territories, such as Recordati in its territory, and obtain additional product approvals; competition in the ED market and other markets in which Apricus and its partners operate; Apricus’ ability to obtain and maintain intellectual property protection for the product; Apricus’ ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; Apricus’ ability to obtain FDA and other requisite governmental approval for Vitaros; the fluctuation of currency exchange rates; the potential for adverse reactions to the product; Apricus’ ability to negotiate and enter into acceptable terms for new licensing agreements; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus’ most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov  or without charge from Apricus.

Contact: Matthew Beck mbeck@troutgroup.com The Trout Group LLC (646) 378-2933

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 205

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 327

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 221

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 299

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 287

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 264

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Challenges Ahead for Beyond Meat Despite Steady Price Target

Updated Category News Views 126

Beyond Meat's Current Stock Evaluation Piper Sandler continues to maintain its underweight rating on Beyond Meat Inc. (NASDAQ: BYND), keeping a price target steadfast at $3.00. This decision follows insights gained from their extensive Teen Survey, which engaged around 13,500 participants about their views on plant-based meat products. Survey Insights and Teen Trends The...

Continue Reading
LaFleur Minerals Paves the Way for Gold Mill Restart with Drilling

Updated Category News Views 194

LaFleur Minerals Focuses on Gold Production Enhancement Lafleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) is making significant strides towards initiating gold production with the recent commencement of a confirmation drilling program at its Swanson Gold Deposit. Located in a region rich in mineral resources, this initiative aims to gather essential data for a Preliminary...

Continue Reading
Understanding the Class Action Involving Integral Ad Science

Updated Category News Views 187

Important Update for Integral Ad Science Investors Integral Ad Science Holding Corp. (NASDAQ: IAS) investors should be aware of a crucial class action lawsuit. Legal representation is being provided by Kirby McInerney LLP, a trusted law firm, assisting affected individuals in navigating their rights and interests concerning this matter. Understanding the Class Action...

Continue Reading
Netformx and Ingram Micro Launch API to Enhance Sales Insights

Updated Category News Views 135

Netformx and Ingram Micro Team Up for an Innovative API Solution In an exciting partnership, Netformx, an industry leader in automation tools for IT solution providers, announced a new API collaboration with Ingram Micro. This integration aims to provide channel partners with a seamless view of their sales pipelines, enabling improved planning and enhanced deal...

Continue Reading
Purpose Healing Center Marks 8 Years of Service and Commitment

Updated Category News Views 185

Purpose Healing Center Marks 8 Years of Impact in Behavioral Health Purpose Healing Center, a prominent behavioral health and substance use treatment provider based in Scottsdale, Arizona, proudly celebrates its eighth anniversary of serving AHCCCS members statewide. The organization has made significant strides toward enhancing access to critical mental health services...

Continue Reading